Comment: Zumilokibart (APG-777) is an interleukin 13 (IL-13) neutralising monoclonal antibody [1,3]. It is engineered to have an extended circulating half-life [2].
Binding to IL-13 prevents formation of the functionally active IL-13/IL‐13Rα1/IL‐4Rα complex, that would otherwise induce an inflammatory response via the JAK1/2-STAT6 pathway.